Company intelligence / Profile preview
Evozyne
Chicago, Illinois, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Evozyne uses generative AI to design novel therapeutic proteins, aiming to address unmet medical needs and sustainability challenges. The company has not disclosed specific clinical trial data; focus remains on platform development and early-stage protein candidates.
- Therapeutic areas
- Other
- Modalities
- ProteinEnzyme (as described, e.g., gene editors, immune-modulating enzymes)Gene therapy (via gene editors)
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Takeda (research collaboration and license agreement for gene therapy engineering)NVIDIA (collaboration on generative AI models for protein design)
Beyond the preview
Go deeper on Evozyne.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evozyne.